EUVIMEDEUVIMED entdecken
Crossref

Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience

Yuxue Nie, Nianyi Zhang, Jingna Li, Di Wu, Yunjiao Yang, Li Zhang, Wei Bai, Nan Jiang, Lin Qiao, Can Huang, Shuang Zhou, Xinping Tian und 4 weitere

Journal of Clinical Immunology · 2024-11 · 44 (8)

DOI: 10.1007/s10875-024-01773-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Immunology, online erschienen am 16.08.2024. Verfasst von Yuxue Nie und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical…. Hauptthemen laut MEDLINE: Rituximab, Agammaglobulinemia, Autoimmune Diseases, Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To investigate predictors of hypogammaglobulinemia (HGG) and severe infection event (SIE) in patients with autoimmune disease (AID) receiving rituximab (RTX) therapy. METHODS: This was a retrospective study conducted in a tertiary medical center in China. Predictors of HGG or SIE were assessed using Cox analysis. Restricted cubic spline (RCS) analysis was applied to examine the correlation between glucocorticoid (GC) maintenance dose and SIE. RESULTS: A total of 219 patients were included in this study, with a cumulative follow-up time of 698.28 person-years. Within the study population, 117 patients were diagnosed with connective tissue disease, 75 patients presented with ANCA-associated vasculitis, and 27 patients exhibited IgG4-related disease. HGG was reported in 63.3% of the patients, where an obvious decline in IgG and IgM was shown three months after RTX initiation. The rate of SIE was 7.2 per 100 person-years. An increase in the GC maintenance dose was an independent risk factor for both hypo-IgG (HR 1.07, 95% CI 1.02-1.12, p = 0.003) and SIE (HR 1.06, 95% CI 1.02-1.1, p = 0.004). Further RCS analysis identified 7.48 mg/d prednisone as a safe threshold dose for patients who underwent RTX treatment to avoid a significantly increased risk for SIE. CONCLUSION: HGG was relatively common in RTX-treated AID patients. Patients with chronic lung disease or who were taking ≥ 7.5 mg/d prednisone during RTX treatment were at increased risk for SIE and warrant attention from physicians.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabAgammaglobulinemiaAutoimmune DiseasesInfectionsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedGlucocorticoidsRisk FactorsChinaImmunoglobulin G

Stichwörter der Autor:innen

Autoimmune diseaseHypogammaglobulinemiaImmunoglobulinsRituximabSevere infection event

Substanzen

RituximabGlucocorticoidsImmunoglobulin G

Autor:innen und Institutionen

  • Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immun…

Förderung

  • National High Level Hospital Clinical Research Funding
  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • Beijing Natural Science Foundation
  • National Key Research and Development Program of China

Zitieren

APA

Nie, Y., Zhang, N., Li, J., Wu, D., Yang, Y., Zhang, L., Bai, W., Jiang, N., Qiao, L., Huang, C., Zhou, S., Tian, X., Li, M., Zeng, X., Peng, L., & Zhang, W. (2024). Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience. Journal of Clinical Immunology, 44(8). https://doi.org/10.1007/s10875-024-01773-y

Vancouver

Nie Y, Zhang N, Li J, Wu D, Yang Y, Zhang L, et al. Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience. Journal of Clinical Immunology. 2024;44(8). doi:10.1007/s10875-024-01773-y

BibTeX
@article{Nie2024,
  author = {Nie, Yuxue and Zhang, Nianyi and Li, Jingna and Wu, Di and Yang, Yunjiao and Zhang, Li and Bai, Wei and Jiang, Nan and Qiao, Lin and Huang, Can and Zhou, Shuang and Tian, Xinping and Li, Mengtao and Zeng, Xiaofeng and Peng, Linyi and Zhang, Wen},
  title = {Hypogammaglobulinemia and Infection Events in Patients with Autoimmune Diseases Treated with Rituximab: 10 Years Real-Life Experience},
  journal = {Journal of Clinical Immunology},
  year = {2024},
  volume = {44},
  number = {8},
  doi = {10.1007/s10875-024-01773-y}
}
Kostenlos starten →